REFERENCE FILE
Cagrilintide
Examine the reference details alongside the questions and dated sources.
Reference details
Status as of
- Regulatory category
- Investigational
- Evidence category
- Randomized evidence
- Mechanism
- A long-acting amylin analogue.
- Evidence
- A randomized weight-management trial was funded by Novo Nordisk.
- Limitations
- Combination results cannot be assigned to a single ingredient.
- Safety
- The trial reported gastrointestinal and injection-site reactions.
- Formulation and route
- Studied as a subcutaneous injection.
- Approval scope
- Investigational; no FDA-approved product.
READING NOTES
Questions for a closer look
Take one sentence about cagrilintide and identify its operative verb: what does it say changed, improved or was established? Find the outcome definition offered as support and describe the observation needed to satisfy it. Now ask whether that observation would justify the full sentence or only a narrower version. Draft the narrower version without strengthening its certainty. This is a wording exercise, not a request to choose the most appealing result. Keep any unverified link between the measured outcome and the broader claim visible as a question, and name the additional observation that would address it.
Questions to investigate
- What does the claim's operative verb ask the evidence to establish?
- Which observation would satisfy the outcome definition offered as support?
- What additional observation would justify the broader wording of the claim?
Sources for this file
MED CONSUMER WATCH · RESEARCH
Read the evidence behind the question.
Browse reference files or follow a study analysis from its question to its limitations.